Ulrik Niels Lassen
Clinical Professor
- 2019
- Published
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J. P., Arkenau, H. T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., Rangwala, R. A. & 1 others, , 2019, In: The Lancet Oncology. 20, 3, p. 383-393 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
- 2018
- Published
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors
Ahlborn, L. B., Tuxen, I. V., Mouliere, F., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W., Oestrup, O. & Mau-Sorensen, M., 2018, In: OncoTarget. 9, 66, p. 32570-32579Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V. & 18 others, , 2018, In: The New England Journal of Medicine. 378, 8, p. 731-739Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Patient information in phase 1 trials: A systematic review
Gad, K. T., Lassen, Ulrik Niels, Mau-Søerensen, M., Høybye, M. T. & Johansen, Christoffer, Mar 2018, In: Psycho-Oncology. 27, 3, p. 768-780Research output: Contribution to journal › Review › Research › peer-review
- Published
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors
Johansen, M. D., Urup, T., Holst, C. B., Christensen, I. J., Grunnet, K., Lassen, Ulrik Niels, Friis, S. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 9-10, p. 512-519 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Kummar, S. & Lassen, Ulrik Niels, 2018, In: Targeted Oncology. 13, 5, p. 545-556Research output: Contribution to journal › Review › Research › peer-review
- Published
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
Massard, C., Azaro, A., Soria, J., Lassen, Ulrik Niels, Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, 9, p. 1911-1917 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
Michaelsen, Signe Regner, Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T., Villingshøj, M., Lukacova, S., Skjøth-Rasmussen, J., Brennum, J., Kjær, Andreas, Lassen, Ulrik Niels, Stockhausen, M., Poulsen, H. S. & Hamerlik, P., 2018, In: Neuro-Oncology. 20, 11, p. 1462-1474Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival
Michaelsen, Signe Regner, Urup, T., Olsen, L. R., Broholm, H., Lassen, Ulrik Niels & Poulsen, H. S., 2018, In: Journal of Neuro-Oncology. 137, 3, p. 533-542 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Schneeweiss, A., Park-Simon, T. W., Albanell, J., Lassen, U., Cortés, J., Dieras, V., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., Martinez-Garcia, M., Gonzalez, I., Lopez-Martin, J., Welt, A., Levy, C., Joly, F., Michielin, F., Jacob, W., Adessi, C., Moisan, A. & 7 others, , 2018, In: Investigational New Drugs. 36, 5, p. 848-859 12 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 4952653
Most downloads
-
480
downloads
Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
224
downloads
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
174
downloads
Hallmarks of glioblastoma: a systematic review
Research output: Contribution to journal › Review › Research › peer-review
Published